Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,652 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all

Conditions: Schizophrenia
Interventions: Ziprasidone; Drug
Lead sponsor: North Suffolk Mental Health Association; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Lurasidone HCl; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 27
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 21 more

Conditions: Schizophrenia
Interventions: multifamily group-adherence, multifamily group-standard; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Granada Hills, California

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: LY03004, Risperdal® Consta®; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Little Rock, Arkansas • Long Beach, California • Orange, California + 7 more

Conditions: Schizophrenia
Interventions: Valacyclovir HCI 500 mg tablets, placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 13
States / cities: Bellflower, California • Los Angeles, California • Riverside, California + 9 more

Conditions: Schizophrenia
Interventions: CAD-9303, Placebos; Drug
Lead sponsor: Cadent Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Schizophrenia
Interventions: Antipsychotic medication adherence intervention; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: No. Little Rock, Arkansas

Conditions: Schizophrenia
Interventions: Aripiprazole, Risperidone; Drug
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Schizophrenia
Interventions: Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System; Device
Lead sponsor: ERP Biomarker Qualification Consortium; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Garden Grove, California • Torrance, California • Marlton, New Jersey + 1 more

Conditions: Schizophrenia
Interventions: Active tDCS + Auditory Training, Active tDCS + Control Condition, Sham tDCS + Auditory Training; Combination Product
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: RGH-188; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Schizophrenia
Interventions: Dronabinol, Placebo Comparator; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Schizophrenia
Interventions: Oxytocin, Placebo, Social Cognitive Skills Training; Drug · Other · Behavioral
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia, Schizophrenia Schizoaffective
Interventions: PLIFUS, Sham PLIFUS, MRI; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Depression, Anxiety, Psychosis
Interventions: Participatory technology development, Usual Care; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: paliperidone palmitate, oral risperidone; Drug
Lead sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 23
States / cities: Little Rock, Arkansas • Garden Grove, California • San Diego, California + 20 more

Conditions: Schizophrenia
Interventions: ML-007C-MA; Drug
Lead sponsor: MapLight Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 45
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 39 more

Conditions: Schizophrenia Spectrum & Other Psychotic Disorders
Interventions: Patient Aligned Care Team (PACT); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 3
States / cities: San Diego, California • West Los Angeles, California • Las Vegas, Nevada

Conditions: Major Depressive Disorder, Schizo Affective Disorder, Schizophrenia, Bipolar Disorder
Interventions: Behavior Activation; Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Psychotic Disorders
Interventions: Forensic Assertive Community Treatment (FACT), Enhanced Treatment as Usual; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Schizophrenia, Schizo Affective Disorder
Interventions: Emotional working memory training, Placebo working memory training; Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 60 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Schizophrenia Disorders
Interventions: Brief Activities; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Late Onset Schizophrenia, Delusional Disorder (Late Onset)
Interventions: Tau PET imaging scan; Diagnostic Test
Lead sponsor: Jeremy Koppel; Other
Eligibility: 65 Years to 85 Years
Enrollment: 16 participants
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Schizophrenia
Interventions: Functional Adaptation Skills Training (FAST); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Promoting Adherence to Treatment in Schizophrenia

Bioavailability of LY03004 and Risperdal® Consta®

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

Study of CAD-9303 in Subjects With Schizophrenia

Patient-Centered Medication Adherence Intervention for Schizophrenia

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

Event-Related Potential (ERP) Biomarkers in Subjects With Schizophrenia and Healthy Volunteer Subjects

Transcranial Direct Current Stimulation and Effects on Early Auditory Processing in Schizophrenia

Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

Pharmacological Approach to Improve the Outcome of Social Cognition Training

Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia

Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

PACT for Individuals With Serious Mental Illness

Getting Out of the House: Using Behavioral Activation to Increase Community Participation

Forensic Assertive Community Treatment: An Emerging Model of Service Delivery

Cognitive Training for Emotion Regulation in Psychotic Disorders

Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy Controls

Tau Biomarkers in Late-onset Psychosis (LOP)

Rehabilitative Training for Older People With Schizophrenia